Evaluation of Four Point of Care (POC) Antigen Assays for the Detection of the SARS-CoV-2 Variant Omicron
Justin Hardick, Nicholas Gallagher, Jaiprasath Sachithanandham, Amary Fall, Zishan K. Siddiqui, Andrew Pekosz, Yukari C. Manabe, Heba H. Mostafa
Abstract
TCID50/mL, respectively. We further quantified the viral stocks used by droplet digital (ddPCR) and found that the Omicron stock had equivalent copies of the N gene to Delta at a one log lower infectious virus titer and that an increased RNA to infectious virus ratio may be contributing to discrepancies in limit of detection in Omicron compared to Delta. We evaluated 14 SARS-CoV-2 real-time PCR positive nasal/nasopharyngeal swab samples (12 Omicron and 2 Delta), with an average cycle threshold value of 19.1, and only the QuickVue showed 100% agreement.
Topics & Concepts
Point of careSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntigenCoronavirus disease 2019 (COVID-19)VirologyMedicinePoint-of-care testingMolecular biologyBiologyImmunologyPathologyDiseaseInfectious disease (medical specialty)SARS-CoV-2 detection and testingSARS-CoV-2 and COVID-19 ResearchBiosensors and Analytical Detection